[go: up one dir, main page]

WO2005097179A3 - Antigene tat stabilise et ses applications pour la vaccination anti-vih. - Google Patents

Antigene tat stabilise et ses applications pour la vaccination anti-vih. Download PDF

Info

Publication number
WO2005097179A3
WO2005097179A3 PCT/FR2005/000795 FR2005000795W WO2005097179A3 WO 2005097179 A3 WO2005097179 A3 WO 2005097179A3 FR 2005000795 W FR2005000795 W FR 2005000795W WO 2005097179 A3 WO2005097179 A3 WO 2005097179A3
Authority
WO
WIPO (PCT)
Prior art keywords
stabilised
tat antigen
hiv vaccination
hiv
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/000795
Other languages
English (en)
Other versions
WO2005097179A2 (fr
Inventor
Pascal Drevet
Evelyne Lajeunesse
Alain Lecoq
Michel Leonetti
Andre Menez
Gervaise Moine
Robert Thai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to US10/599,448 priority Critical patent/US8501193B1/en
Priority to CA002561163A priority patent/CA2561163A1/fr
Priority to JP2007505601A priority patent/JP5065004B2/ja
Priority to EP05746800A priority patent/EP1737959A2/fr
Priority to AU2005230425A priority patent/AU2005230425B2/en
Publication of WO2005097179A2 publication Critical patent/WO2005097179A2/fr
Priority to IL178311A priority patent/IL178311A0/en
Anticipated expiration legal-status Critical
Publication of WO2005097179A3 publication Critical patent/WO2005097179A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention est relative à une composition vaccinale comprenant au moins une composition vaccinale anti-VIH comprenant au moins un antigène Tat stabilisé, ainsi qu'à ses applications pour la prévention et/ou le traitement d'une infection par le VIH chez l'Homme.
PCT/FR2005/000795 2004-04-01 2005-04-01 Antigene tat stabilise et ses applications pour la vaccination anti-vih. Ceased WO2005097179A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/599,448 US8501193B1 (en) 2004-04-01 2005-04-01 Stabilized Tat antigen and the use thereof for anti-HIV vaccination
CA002561163A CA2561163A1 (fr) 2004-04-01 2005-04-01 Antigene tat stabilise et ses applications pour la vaccination anti-vih
JP2007505601A JP5065004B2 (ja) 2004-04-01 2005-04-01 安定化Ｔａｔ抗原及び抗ＨＩＶワクチン接種のためのその使用
EP05746800A EP1737959A2 (fr) 2004-04-01 2005-04-01 Antigene tat stabilise et ses applications pour la vaccination anti-vih
AU2005230425A AU2005230425B2 (en) 2004-04-01 2005-04-01 Stabilised Tat antigen and the use thereof for anti-HIV vaccination
IL178311A IL178311A0 (en) 2004-04-01 2006-09-26 Stabilised tat antigen and the use thereof for anti-hiv vaccination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403429A FR2868318B1 (fr) 2004-04-01 2004-04-01 Antigene tat stabilise et ses applications pour la vaccination anti-vih
FR0403429 2004-04-01

Publications (2)

Publication Number Publication Date
WO2005097179A2 WO2005097179A2 (fr) 2005-10-20
WO2005097179A3 true WO2005097179A3 (fr) 2006-10-19

Family

ID=34945837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/000795 Ceased WO2005097179A2 (fr) 2004-04-01 2005-04-01 Antigene tat stabilise et ses applications pour la vaccination anti-vih.

Country Status (9)

Country Link
US (1) US8501193B1 (fr)
EP (1) EP1737959A2 (fr)
JP (1) JP5065004B2 (fr)
AU (1) AU2005230425B2 (fr)
CA (1) CA2561163A1 (fr)
FR (1) FR2868318B1 (fr)
IL (1) IL178311A0 (fr)
WO (1) WO2005097179A2 (fr)
ZA (1) ZA200608278B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206239B2 (en) 2009-03-23 2015-12-08 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008089494A2 (fr) * 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Procédés d'utilisation de composés inhibiteurs epsilon pour l'atténuation de la douleur
FR2955773B1 (fr) 2010-02-01 2017-05-26 Commissariat Energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
CN105705164A (zh) 2013-10-04 2016-06-22 品诺制药公司 用于癌症治疗的免疫刺激性hiv tat衍生多肽
US11384138B2 (en) 2015-08-19 2022-07-12 Rutgers, The State University Of New Jersey Methods of generating antibodies

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002185A1 (fr) * 1997-07-11 1999-01-21 Thymon L.L.C. Procedes et compositions pour empecher la multiplication de l'hiv-1
WO2000061067A2 (fr) * 1999-04-13 2000-10-19 Centre National De La Recherche Scientifique (Cnrs) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
WO2001054719A2 (fr) * 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Nouvelle utilisation
WO2001082944A1 (fr) * 2000-04-28 2001-11-08 Thymon L.L.C. Procedes et compositions visant a compromettre la multiplication du vih-1
WO2003011334A1 (fr) * 2001-07-27 2003-02-13 Glaxosmithkline Biologicals S.A. Nouvelle utilisation
WO2003054006A2 (fr) * 2001-12-11 2003-07-03 Aventis Pasteur Proteine tat de vih mutee
WO2003057885A1 (fr) * 2002-01-11 2003-07-17 Biomerieux S.A. Mutants de la proteine tat du virus vih-1
WO2004024173A2 (fr) * 2002-09-13 2004-03-25 Creabilis Therapeutics S.P.A. Nouveau mecanisme d'entree du vih-1 dans des cellules hotes et peptides inhibant ce mecanisme

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
EP1246647B1 (fr) * 1999-08-12 2010-04-28 InIst, Inc. Proteines tat non immunosuppressives de vih
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002185A1 (fr) * 1997-07-11 1999-01-21 Thymon L.L.C. Procedes et compositions pour empecher la multiplication de l'hiv-1
WO2000061067A2 (fr) * 1999-04-13 2000-10-19 Centre National De La Recherche Scientifique (Cnrs) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
WO2001054719A2 (fr) * 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Nouvelle utilisation
WO2001082944A1 (fr) * 2000-04-28 2001-11-08 Thymon L.L.C. Procedes et compositions visant a compromettre la multiplication du vih-1
WO2003011334A1 (fr) * 2001-07-27 2003-02-13 Glaxosmithkline Biologicals S.A. Nouvelle utilisation
WO2003054006A2 (fr) * 2001-12-11 2003-07-03 Aventis Pasteur Proteine tat de vih mutee
WO2003057885A1 (fr) * 2002-01-11 2003-07-17 Biomerieux S.A. Mutants de la proteine tat du virus vih-1
WO2004024173A2 (fr) * 2002-09-13 2004-03-25 Creabilis Therapeutics S.P.A. Nouveau mecanisme d'entree du vih-1 dans des cellules hotes et peptides inhibant ce mecanisme

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALBINI ADRIANA ET AL: "HIV-tat protein is a heparin-binding angiogenic growth factor", ONCOGENE, vol. 12, no. 2, 1996, pages 289 - 297, XP009054105, ISSN: 0950-9232 *
CAFARO A ET AL: "Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 6, June 1999 (1999-06-01), pages 643 - 650, XP002254323, ISSN: 1078-8956 *
CHANG HSIAO C ET AL: "HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region", AIDS (LONDON), vol. 11, no. 12, 1997, pages 1421 - 1431, XP002364046, ISSN: 0269-9370, Retrieved from the Internet <URL:http://gateway.ut.ovid.com/gw1/ovidweb.cgi> *
HAKANSSON SUSANNA ET AL: "Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states.", BIOCHEMISTRY, vol. 42, no. 30, 5 August 2003 (2003-08-05), pages 8999 - 9006, XP002346128, ISSN: 0006-2960 *
MARCHIO SERENA ET AL: "Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein", BLOOD, vol. 105, no. 7, April 2005 (2005-04-01), pages 2802 - 2811, XP002346131, ISSN: 0006-4971 *
MISUMI SHOGO ET AL: "Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 20, no. 3, March 2004 (2004-03-01), pages 297 - 304, XP002303795, ISSN: 0889-2229 *
NOONAN DOUGLAS M ET AL: "Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers.", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999) 1 MAY 2003, vol. 33, no. 1, 1 May 2003 (2003-05-01), pages 47 - 55, XP009036540, ISSN: 1525-4135 *
PAUZA C DAVID ET AL: "Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 7, 28 March 2000 (2000-03-28), pages 3515 - 3519, XP002346127, ISSN: 0027-8424 *
RUSNATI MARCO ET AL: "The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 26, 26 June 1998 (1998-06-26), pages 16027 - 16037, XP002346130, ISSN: 0021-9258 *
WATSON KEITH ET AL: "Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides", BIOCHEMICAL PHARMACOLOGY, vol. 57, no. 7, 1 April 1999 (1999-04-01), pages 775 - 783, XP002346129, ISSN: 0006-2952 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206239B2 (en) 2009-03-23 2015-12-08 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides

Also Published As

Publication number Publication date
ZA200608278B (en) 2009-05-27
AU2005230425B2 (en) 2011-08-25
US8501193B1 (en) 2013-08-06
JP2007530647A (ja) 2007-11-01
FR2868318A1 (fr) 2005-10-07
IL178311A0 (en) 2007-02-11
EP1737959A2 (fr) 2007-01-03
FR2868318B1 (fr) 2012-11-16
AU2005230425A1 (en) 2005-10-20
JP5065004B2 (ja) 2012-10-31
CA2561163A1 (fr) 2005-10-20
WO2005097179A2 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
IL180947A0 (en) Vaccine for prevention and treatment of hiv infection
WO2007030810A3 (fr) Moniteur de sang total multiparametrique et procede associe
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
WO2002032943A3 (fr) Modifications de env, gag, et pol de vih a pouvoir immunogene augmente aux fins d&#39;immunisation genetique
WO2004015099A3 (fr) Compositions de vaccins
CY1111636T1 (el) Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv
IL150961A0 (en) Human immunodeficiency virus vaccine
WO2004045529A3 (fr) Vaccin contre le virus du nil occidental
WO2003059385A3 (fr) Vaccin contre le vih et procede d&#39;utilisation
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
WO2007002470A3 (fr) Vaccins chimeres inactives et leurs procedes d&#39;utilisation
WO2005028496A3 (fr) Vaccin pour le traitement et la prevention de l&#39;infection provoquee par le virus de l&#39;herpes simplex
WO2008057158A3 (fr) Nouvel immunogène de neutralisation (nimiv) de rhinovirus et son utilisation pour des applications dans la vaccination
WO2005097179A3 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih.
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2006034001A3 (fr) Procedes de traitement de l&#39;infection par vih
WO2002060936A3 (fr) Vaccin et compositions permettant de prevenir et de traiter des infections induites par neisseria
WO2003053338A3 (fr) Nouveaux antigenes rev, tat, et nef chimeriques
WO2005089231A3 (fr) Activite renforcee de vaccin vih utilisant un oligonucleotide immunomodulateur de seconde generation
WO2003101482A3 (fr) Formulations de vaccins associes a des liposomes, destinees a des poissons a nageoires
WO2004110373A3 (fr) Compositions vaccinales therapeutiques servant a traiter le diabete de type 1
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
IL236509A0 (en) Use of one or more hbv antigens for the preparation of oral pharmaceutical compositions for treating a subject having an active hbv infection or hepatocellular carcinoma
WO2003045428A3 (fr) Utilisation d&#39;une cellule techniquement modifiee en tant que vaccin pour traiter une tumeur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2561163

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 178311

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005230425

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007505601

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 200608278

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 6069/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005230425

Country of ref document: AU

Date of ref document: 20050401

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005230425

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005746800

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005746800

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10599448

Country of ref document: US